Saturday, July 11, 2026

pharma · Relapsing-Remitting Multiple Sclerosis · Spinal Muscular Atrophy

Biogen

Biogen is a pharma organization headquartered in VISAKHAPATNAM, IN. Primary therapeutic focus areas include Relapsing-Remitting Multiple Sclerosis, Spinal Muscular Atrophy, systemic lupus erythematosus, IgA nephropathy,

225 Binney Street, Cambridge, MA 02142, US HQ
7,534 Employees
NMPA registrant Type
Company details
Clinical program

dimethyl fumarate

Phase 3 · small molecule · Relapsing-Remitting Multiple Sclerosis

dimethyl fumarate for Relapsing-Remitting Multiple Sclerosis is a Phase 3 program (small_molecule) at Biogen with 1 ClinicalTrials.gov record(s).

← All Biogen projects Phase 3 small molecule completed

Internal code 109MS303

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Biogen
Phase
Phase 3
Modality
small_molecule
Indication
Relapsing-Remitting Multiple Sclerosis
Status
completed
Trials
1